← Back to Clinical Trials
Recruiting EARLY_Phase 1 NCT04592640
Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis
Trial Parameters
Condition Chronic Kidney Diseases
Sponsor The First Affiliated Hospital with Nanjing Medical University
Study Type INTERVENTIONAL
Phase EARLY_Phase 1
Enrollment 9
Sex ALL
Min Age 18 Years
Max Age 75 Years
Start Date 2018-09-17
Completion 2027-09-17
All Conditions
Interventions
Human amniotic-derived mesenchymal stem cells
Brief Summary
Treatment for Calciphylaxis Patients with Human Amniotic-derived Mesenchymal Stem Cells
Eligibility Criteria
Inclusion Criteria: 1. 18-75 years old. 2. Clinical diagnosis of calciphylaxis, including patients with chronic kidney disease who did not or had regular dialysis (hemodialysis or peritoneal dialysis). 3. All subjects signed informed consent. Exclusion criteria: 1. Patients who refuse to sign informed consent. 2. Patients with malignant tumors or severe psychiatric disorders, or an expected survival time of less than 6 months. 3. Pregnant or lactating women of childbearing age. 4. Participation in another clinical trial with an experimental drug within 90 days prior the inclusion.
Related Trials
NCT06322056
Exploring Approaches With Lower Targets of Blood Pressure and Lipid for Improving Renal Outcome in A
View Trial →
NCT04522622
Treatment of Adynamic Bone Disorder With Parathyroid Hormone in Chronic Kidney Disease
View Trial →
NCT06738394
Enhancing Physical Function in Older Adults With Chronic Kidney Disease
View Trial →